FILTER
FILTERED INTERVIEW RESULTS
Richard Ansong
PARTNER, PWC GHANA
PwC Ghana updates GBR on the countries financial and regulatory conditions.
Kwame Amponsah
GENERAL MANAGER, RAMOTH SERVICES
Ramoth Services supports mines with engineering and construction in Ghana.
NanaAma Botchway
MANAGING PARTNER, N. DOWUONA & COMPANY
N. Dowuona & Company is a predominantly female-owned and led law firm in Ghana and describes regulatory conditions for mining.
Seth Asante
MANAGING PARTNER, BENTSI-ENCHILL, LETSA & ANKOMAH (BELA)
Ghanian law firm BELA explains recent changes to the country’s mining regulations.
Peter De Leo
MANAGING DIRECTOR, LYCOPODIUM LIMITED
Lycopodium is an ASX-listed global engineering and project delivery organisation from Perth, Australia with operations across Africa.
Federico De Simone
DIRECTOR, DE SIMONE GROUP
"The high raw material prices create a two-sided situation whereby some economies are helped by the high prices, while some sectors suffer due to heightened costs."
Sampson Koduah
WEST AFRICA GENERAL MANAGER, INTERTEK MINERALS
"Many new players are joining the market, while those who have kept a low profile over the years are now resurfacing, stronger."
Baafour Asiamah-Adjei
CEO AND FOUNDER, GENSER ENERGY
"Our strategy is to enter the Sahelian countries with a combination of renewable energy and trucked LNG from Ghana."
Simon Meadows Smith
MANAGING DIRECTOR, SEMS EXPLORATION
"Across the region, the old model of flying in expats to do the technical job combined with a few locals doing the rest of the work on the ground has to change and has started to change."
George Ankomah
PARTNER, DELOITTE GHANA
"Deloitte is a key stakeholder to the industry, providing input in the development of various mining laws over the years."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
